Branched stent graft sales will rise through 2036, driven by FEVAR at 46.2% of the application outlook segment in 2026. The market was valued at USD 483.88 million in 2025 and is expected to be worth USD 1006.60 million by 2036, creating an incremental opportunity of USD 645.62 million.